Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMYESXB)

Drug Name

4-[2-(2-Thienyl)acetamido]benzenesulfonamide Drug Info

Synonyms

N-(4-sulfamoylphenyl)-2-(thiophen-2-yl)acetamide; N-(4-Sulfamoyl-phenyl)-2-thiophen-2-yl-acetamide; 4-[2-(2-Thienyl)acetamido]benzenesulfonamide; sulfonamide deriv., 5a; AC1LDN6X; Cambridge id 6617099; Oprea1_255870; Oprea1_090963; MLS001212957; CHEMBL573127; ZINC30817; BDBM35726; MolPort-000-681-412; 3r16; HMS1588L03; HMS2848H14; CCG-19182; STK001094; AKOS000646514; MCULE-6253669570; 349432-97-9; SMR000518066; BAS 03030369; ST043878; N-(4-sulfamoylphenyl)-2-(2-thienyl)acetamide; N-(4-sulfamoylphenyl)-2-thiophen-2-ylacetamide

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 670143
TTD Drug ID: DMYESXB

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Carbonic anhydrase (CA)	TTUNARX	NOUNIPROTAC	Inhibitor	[1]
Carbonic anhydrase I (CA-I)	TTHQPL7	CAH1_HUMAN	Inhibitor	[1]
Carbonic anhydrase II (CA-II)	TTANPDJ	CAH2_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Carbonic anhydrase I (CA-I)	DTT	CA1	5.564	11.952	6.146	7.235
Carbonic anhydrase II (CA-II)	DTT	CA2	8.796	10.933	9.395	9.819

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Discovery agent

ICD Disease Classification

N.A.

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Carbonic anhydrase I (CA-I)	DTT	CA1	5.23E-14	-0.11	-0.41
Carbonic anhydrase II (CA-II)	DTT	CA2	7.95E-08	0.52	0.33

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9.